pub 30-day FRN

khammond on DSKJM1Z7X2PROD with NOTICES

Federal Register / Vol. 87, No. 179 / Friday, September 16, 2022 / Notices
third and final Report to Congress and
the HHS Secretary. The 2022 report will
address a wide range of topics related to
tick-borne diseases, such as,
surveillance, prevention, diagnosis,
diagnostics, and treatment; identify
advances made in research, as well as
overlap and gaps in tick-borne disease
research; and provide recommendations
regarding any appropriate changes or
improvements to such activities and
research.
DATES: The public can view the meeting
online via webcast on October 25, 2022
from approximately 9:00 a.m. to 5:00
p.m. ET (times are tentative and subject
to change) each day. The confirmed
times and agenda items for the meeting
will be posted on the TBDWG web page
at https://www.hhs.gov/ash/advisorycommittees/tickbornedisease/meetings/
2022-10-25/index.html when this
information becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the TBDWG; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
Services, Tower Building, 1101 Wootton
Parkway, Rockville, MD 20852. Email:
[email protected]. Phone: 202–
795–7608.
SUPPLEMENTARY INFORMATION: A link to
view the webcast can be found on the
meeting website at https://www.hhs.gov/
ash/advisory-committees/
tickbornedisease/meetings/2022-10-25/
index.html when it becomes available.
The public will have an opportunity to
present their views to the TBDWG orally
during the meeting’s public comment
session or by submitting a written
public comment. Comments should be
pertinent to the meeting discussion.
Persons who wish to provide verbal or
written public comment should review
instructions at https://www.hhs.gov/
ash/advisory-committees/
tickbornedisease/meetings/2022-10-25/
index.html and respond by midnight
October 17, 2022 ET. Verbal comments
will be limited to three minutes each to
accommodate as many speakers as
possible during the 30-minute session.
Written public comments will be
accessible to the public on the TBDWG
web page prior to the meeting.
Background and Authority: The TickBorne Disease Working Group was
established on August 10, 2017, in
accordance with section 2062 of the 21st
Century Cures Act, and the Federal
Advisory Committee Act, 5 U.S.C. app.,
as amended, to provide expertise and
review federal efforts related to all tickborne diseases, to help ensure
interagency coordination and minimize

VerDate Sep<11>2014

16:43 Sep 15, 2022

Jkt 256001

overlap, and to examine research
priorities. The TBDWG is required to
submit a report to the HHS Secretary
and Congress on their findings and any
recommendations for the federal
response to tick-borne disease every two
years.
Dated: September 8, 2022.
James J. Berger,
Designated Federal Officer, Tick-Borne
Disease Working Group, Office of Infectious
Disease and HIV/AIDS Policy.
[FR Doc. 2022–20088 Filed 9–15–22; 8:45 am]
BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Science
Advisory Board for Biosecurity.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (http://videocast.nih.gov/).
Name of Committee: National Science
Advisory Board for Biosecurity.
Date: September 21, 2022.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: The National Science Advisory
Board for Biosecurity (NSABB) meeting will
include a progress update from the NSABB
Working Group to Review and Evaluate
Potential Pandemic Pathogen Care and
Oversight (PC3O) Policy, and stakeholder
engagement on topics related to the U.S.
Government policies for the Oversight of
Dual Use Research of Concern (DURC).
Place: National Institutes of Health, 6705
Rockledge Drive, Suite 630, Bethesda, MD
20892, (Virtual Meeting Link will be
available at https://osp.od.nih.gov/
biotechnology/national-science-advisoryboard-for-biosecurity-nsabb/#meetings).
Contact Person: Cari Young, ScM, Acting
Director, Division of Biosafety, Biosecurity,
and Emerging Biotechnology Policy, Office of
Science Policy, Office of the Director,
National Institutes of Health, 6705 Rockledge
Drive, Suite 630, Bethesda, MD 20892, (301)
594–3746, [email protected].
To sign up to make an oral public comment
at the meeting, please send an email to the
Contact Person listed above at least one
business day prior to the meeting date. Once
all time slots are filled, only written
comments will be accepted. Any interested

PO 00000

Frm 00040

Fmt 4703

Sfmt 4703

56965

person may file written comments by
forwarding the statement to the Contact
Person listed on this notice at least one
business day prior to the meeting date. The
statement should include the name, address,
telephone number and, when applicable, the
business or professional affiliation of the
interested person. Other than name and
contact information, please do not include
any personally identifiable information or
any information that you do not wish to
make public. Proprietary, classified,
confidential, or sensitive information should
not be included in your comments. Please
note that any written comments NIH receives
may be posted unredacted to the Office of
Science Policy website.
Information is also available on the NIH
Office of Science Policy website: https://
osp.od.nih.gov/biotechnology/nationalscience-advisory-board-for-biosecuritynsabb/#meetings, where an agenda, link to
the webcast meeting, and any additional
information for the meeting will be posted
when available. Materials for this meeting
will be posted prior to the meeting. Please
check this website for updates.
This notice is being published less than 15
days prior to the meeting due to scheduling
difficulties.
Dated: September 13, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–20098 Filed 9–15–22; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; The Clinical Trials
Reporting Program (CTRP) Database
(NCI)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
SUMMARY:

E:\FR\FM\16SEN1.SGM

16SEN1

56966

Federal Register / Vol. 87, No. 179 / Friday, September 16, 2022 / Notices

for Public Comments’’ or by using the
search function.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Gisele Sarosy, MD,
Coordinating Center for Clinical Trials
(CCCT), National Cancer Institute, 9609
Medical Center Drive, 6W134,
Rockville, MD 20852 or call non-tollfree number 240–276–6172 or Email
your request, including your address to:
[email protected].

FOR FURTHER INFORMATION CONTACT:

This
proposed information collection was
previously published in the Federal
Register on June 29, 2022, page 38765
(Vol. 87, No. 124) and allowed 60 days
for public comment. One public
comment was received. The purpose of
this notice is to allow an additional 30

SUPPLEMENTARY INFORMATION:

Need and Use of Information
Collection: The Clinical Trials Reporting
Program (CTRP) is an electronic
resource that serves as a single,
definitive source of information about
all NCI-supported clinical research. This
resource allows the NCI to consolidate
reporting, aggregate data, and reduce
redundant submissions. Clinical
research administrators submit
information as designees of clinical
investigators who conduct NCIsupported clinical research. The
designees can electronically access the
CTRP website to complete the initial
trial registration. After registration, four
amendments and four study subject
accrual updates occur per trial annually.

days for public comment. The National
Cancer Institute (NCI), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: The Clinical
Trials Reporting Program (CTRP)
Database (NCI), 0925–0600, Expiration
Date 10/31/2022—EXTENSION,
National Cancer Institute (NCI),
National Institutes of Health (NIH).

OMB approval is requested for three
years. There are no costs to respondents
other than their time. The estimated
annualized burden hours are 18,000.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average time
per response
(in hours)

Total annual
burden hours

Type of respondents

Initial Registration .............................
Amendment .......................................
Update ...............................................
Accrual Updates ................................

Clinical Trials ....................................

3,000
1,500
1,500
3,000

1
4
4
4

1
1
1
15/60

3,000
6,000
6,000
3,000

Totals .........................................

...........................................................

9,000

27,000

........................

18,000

Dated: September 13, 2022.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.

individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

[FR Doc. 2022–20083 Filed 9–15–22; 8:45 am]

Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Animal Genomics Program.
Date: October 25, 2022.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
[email protected].
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Single
Cell Opioid Responses in the Context of HIV
(SCORCH) Program Expansion: CNS Data
Generation for Chronic Opioid,
Methamphetamine, Cocaine and/or
Cannabinoid Exposures.
Date: November 22, 2022.

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings

khammond on DSKJM1Z7X2PROD with NOTICES

Number of
respondents

Form name

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning

VerDate Sep<11>2014

16:43 Sep 15, 2022

Jkt 256001

PO 00000

Frm 00041

Fmt 4703

Sfmt 4703

Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
[email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 12, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–20060 Filed 9–15–22; 8:45 am]
BILLING CODE 4140–01–P

E:\FR\FM\16SEN1.SGM

16SEN1